Sustained vertebral antifracture efficacy of oral anti-osteoporotic therapies in postmenopausal osteoporosis

Current Medical Research and Opinion

Volumn 26, Issue 11, 2010, Pages 2553-2563

  Brandi, M L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Antifracture efficacy; Bisphosphonates; Fracture; Oral anti osteoporotic therapies; Postmenopausal osteoporosis; Sustained antifracture efficacy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; IBANDRONIC ACID; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; INCIDENCE; POSTMENOPAUSE OSTEOPOROSIS; RISK REDUCTION; TREATMENT OUTCOME; VERTEBRA FRACTURE;

AGED; BONE DENSITY CONSERVATION AGENTS; CERVICAL VERTEBRAE; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; THIOPHENES; TREATMENT OUTCOME;

EID: 77958139463     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.519658     Document Type: Article

References (49)

1. Cooper C. The epidemiology of osteoporosis. Osteoporos Int 1999;9 (Suppl. 2):S2-8
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285:785-95
3. Melton III LJ. How many women have osteoporosis now? J Bone Miner Res 1995;10:175-7
4. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726-33
5. EPOS study group. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 2002; 17:716-24
6. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996;11:1010-18
7. Cooper C, O'Neill T, Silman A. The epidemiology of vertebral fractures. European Vertebral Osteoporosis Study Group. Bone 1993;14(Suppl. 1): S89-97
8. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7
9. Cauley JA, Palermo L, Vogt M, et al. Prevalent vertebral fractures in black women and white women. J Bone Miner Res 2008;23:1458-67
10. Cooper C, Atkinson EJ, O'Fallon WM, et al. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992;7:221-7
11. Fink HA, Milavetz DL, Palermo L, et al. What proportion of incident radio-graphic vertebral deformities is clinically diagnosed and vice versa? J Bone Miner Res 2005;20:1216-22
12. Melton III LJ, Atkinson EJ, Cooper C, et al. Vertebral fractures predict subsequent fractures. Osteoporos Int 1999;10:214-21
13. Black DM, Arden NK, Palermo L, et al. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. J Bone Miner Res 1999;14:821-8
14. Ross PD, Davis JW, Epstein RS, et al. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med 1991;114: 919-23
15. Klotzbuecher CM, Ross PD, Landsman PB, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000;15:721-39
16. Cauley JA, Hochberg MC, Lui LY, et al. Long-term risk of incident vertebral fractures. JAMA 2007;298:2761-7
17. Hodsman AB, Leslie WD, Tsang JF, et al. 10-year probability of recurrent fractures following wrist and other osteoporotic fractures in a large clinical cohort. An analysis from the Manitoba Bone Density Program. Arch Intern Med 2008;168:2261-7
18. Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related qualify of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60
19. Carliri A, De Filipis L, Bagnato GL, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-7
20. Brenneman SK, Barrett-Connor E, Sajjan S, et al. Impact of recent fracture on health-related quality of life in postmenopausal women. J Bone Miner Res 2006;21:809-16
21. Oleksik AM, Ewing S, Shen W, et al. Impact of incident vertebral fractures on health related quality of life (HRQOL) in postmenopausal women with prevalent vertebral fractures. Osteoporos Int 2005;16:861-70
22. Fechtenbaum J, Cropet C, Kolta S, et al. The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women. Osteoporos Int 2005;16:2175-79
23. Bianchi ML, Orsini MR, Saraifoger S, et al. Quality of life in post-menopausal osteoporosis. Health Qual Life Outcomes 2005;3:78
24. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800
25. Hall SE, Criddle RA, Comito TL, et al. A case-control study of quality of life and functional impairment in women with long-standing vertebral osteoporotic fractures. Osteoporos Int 1999;9:508-15
26. Huang C, Ross PD, Wasnich RD. Vertebral fracture and other predictors of physical impairment and health care utilization. Arch Intern Med 1996; 156:2469-75
27. Reginster JY, Burlet N. Osteoporosis: a still increasing prevalence. Bone 2006;38(2 Suppl. 1):S4-S9
28. Kanis JA, Burlet N, Cooper C, et al. On behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Osteoporos Int 2008;19:399-428
29. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241-9
30. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 1999;282:1344-52
31. Reginster JY, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
32. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
33. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures; results from the Fracture Intervention Trial. JAMA 1998;280: 2077-82
34. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
35. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87:3609-17
36. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
37. Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009;20:1663-73
38. Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008;67:1736-8
39. Reginster JY, Seeman E, De Vernejoul C, et al. Strontium ranelate reduces the risk of onvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
40. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis. Arthritis Rheum 2008;58: 1687-95
41. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995;333:1437-43
42. Seeman E, Boonen S, Borgström F, et al. Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 2010;46:1038-42
43. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int 2004;75:462-8
44. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alen-dronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-99
45. Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
46. Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedro-nate: a 5-year placebo-controlled clinical experience. Bone 2003;32:120-6
47. Black D, Schwartz A, Ensrud K, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX), a randomized trial. JAMA 2006;296:2927-38
48. Ensrud KE, Barrett-Connor EL, Schwartz A, et al. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial Long-Term Extension Research Group. J Bone Miner Res 2004;19:1259-69
49. Russell RGG, Watts NB, Ebetino FH, et al. Mechanisms of action of bispho-sphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 2008;19:733-59